



JC03 Rec'd PCT 1 2 0C

Dkt. No. 96700/952

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Gary Brian Evans, et al.

Appl. No.

10/524,995 (National Stage of PCT/NZ2003/000186).

I.A. Filing Date

August 21, 2003

For

INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES

AND NUCLEOSIDASES

Customer No.

1912

Examiner

Not yet assigned

Group Unit

Not yet assigned

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

	"Express Mail" mailing label no.	EL 993158122 US					
	Date of Deposit: October 12, 2005						
	I hereby certify that this paper or fee is being						
	deposited with the United States P	ostal Service					
	"Express Mail" service under 37 CFR 1.10 on the date						
	indicated above and is addressed to the						
	Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.						
	Name: Joycelyn Giles Fenty						

Applicants enclose herewith Forms PTO/SB/08A and PTO/SB/08B and copies of the references listed on Forms PTO/SB/08A and PTO/SB/08B. The references were previously cited in the Search Report for PCT Application No. PCT/NZ2003/000186. No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. If any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 01-1785.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN LLP

Attorneys for Applicants 90 Park Avenue

New York, New York 10016

 $(212) \beta 36-8000$

Dated:

October 12, 2005

New York, New York

By:

Craig J. Arnold, Reg. No. 34,287

Page 1 of 1

323883.1

OCT 1 2 2005

OCT 1 2 2005

Substitution 1449/PTO

PTO/SB/08A (07-05)
Approved for the arrough 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known				
Application Number	10/524,995	•		
Filing Date I.A.	August 21, 2003			
First Named Inventor	Gary Brian Evans			
Art Unit				
Examiner Name				
Attorney Docket Number	96700/952			

			U. S. PATENT D	OCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
		US-			
		US-			
		US-		•	- - · · ·
	<u> </u>	US-			
		US-			
•		US-			
		US-			
		US-			

_		FORE	IGN PATENT DOC	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	T
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T
	1	WO 99/19338	04-22-1999	Albert Einstein College of Medicine of Yeshiva Univ.		Ė
	2	WO 02/18371 A1	03-07-2002	Industrial Res. Ltd. and Albert Einstein College of Medicine		
						L
						┝
	<u> </u>					┡

Examiner	Date	=
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

2017
ction Act

PTO/SB/08B (07-05)
Approved for a rough 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

for form 1449/PT(`		Complete if Known		
10110111111	•		Application Number	10/524,995	· · · · ·
RMATIO	N DIS	CLOSURE	Filing Date I.A.	August 21, 2003	
STATEMENT BY APPLICANT			First Named Inventor	Gary Brian Evans	
(11			Art Unit		
(Use as many s	ineets as ne	cessary)	Examiner Name		· -
2	of	2	Attorney Docket Number	96700/952	
	RMATIO TEMENT	(Use as many sheets as ne	PRMATION DISCLOSURE TEMENT BY APPLICANT (Use as many sheets as necessary)	PRMATION DISCLOSURE Filing Date I.A. First Named Inventor Art Unit Examiner Name	Application Number 10/524,995 PRMATION DISCLOSURE Filing Date I.A. August 21, 2003 First Named Inventor Gary Brian Evans Art Unit Examiner Name

		NOVE DESCRIPTION OF THE PROPERTY OF THE PROPER	
Examiner Initials* No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-is number(s), publisher, city and/or country where published.			
	1	EVANS G.B. et al., "Exploring Structure-Activity Relationships of Transition State Analogues of Human Purine Nucleoside Phosphorylase." Journal of Medicinal Chemistry, 46:3412-3423, 2003.	
	2	LEWANSOWICZ A. et al., "Over-the-Barrier Transition State Analogues and Crystal Structure with Mycobacterium Tuberculosis Purine Nucleoside Phosphorylase." Biochemistry, 42:6057-6066, 2003.	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.